The Motley Fool

Novacyt share price surged 2,650% year-to-date! Can this wild ride continue?

AIM-listed Novacyt (LSE:NCYT), a clinical diagnostics specialist, has had an exciting couple of months. The Novacyt share price is up an incredible 2,650% year-to-date!

Its shares surged in April when the World Health Organisation (WHO) fast-tracked Novacyt’s rapid Covid-19 test and recorded the test as eligible for emergency use. Large-scale testing is thought to be key to enabling countries to emerge from lockdown and return to work. This is because it can help track the spread of coronavirus throughout the general population.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

The London-listed biotechnology company has already signed a government contract to provide 288,000 tests per week to the NHS. This is a six-month contract with the option for an extension. In addition, it is supplying 20 hospitals with its test through orders from Public Health England. Primerdesign, a Novacyt subsidiary, is developing the test in Southampton.

Novacyt news and financial update

Novacyt reported its annual results last week, with a net loss of €6.6m for 2019 caused by lower revenue and higher expenses. Revenue for 2019 was €13.1m, compared to €13.7m for 2018, so a disappointing decline in both.

Novacyt is a highly speculative stock with no dividends, negative earnings per share, and a £248m market cap. Nonetheless, it does expect better results this year, as demand for its coronavirus tests increases. The Novacyt share price fell 11% on the release of its annual results, but it is climbing again today and was up over 26% at one point. This proves what a volatile stock this is and not for the faint of heart. 

The future for Novacyt stock

With these contracts in place and recognition from the WHO, it seems Novacyt has cemented itself as a mainstream player. Global demand for Covid-19 testing is continuing and Novacyt also has other products underway, including mobile Covid-19 testing. Its present commitment to growth and expansion is unlike anything it has previously undertaken. I think it will have more than enough to keep it busy this year at least. I do not see its share price having another surge of the same magnitude, but price fluctuations are likely to continue.

If Novacyt can live up to its expectations, then I think it will continue to do well. However, it is still a micro-cap stock on AIM, which means it comes with risk. Pharmaceuticals are a competitive sector to operate in. When trials fail or a product does not meet predictions, the share price suffers. If you are looking to increase your chances of making a million, then I think that ship has sailed for Novacyt.

I hope Novacyt will continue to thrive and survive long after the coronavirus crisis has passed, but I don’t think it is one of the best shares to buy right now. Newcomers to stock market investing should steer clear of speculative investments and look to the long term with more certain investment choices. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.